CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-17 | Vasista Vittal Chief Financial Officer | Sale | −2,394 | $50.00 | $120K | 222,321 |
| 2020-01-17 | HAYDEN DONALD J JR Director | Option exercise | +3,200 | $0.85 | $3K | 3,200 |
| 2020-01-17 | HAYDEN DONALD J JR Director | Sale | −3,200 | $50.01 | $160K | 0 |
| 2020-01-17 | HAYDEN DONALD J JR Director | Option exercise · Stock Option (Right to Buy) | −3,200 | 155,900 | ||
| 2020-01-14 | HAYDEN DONALD J JR Director | Option exercise | +30,000 | $0.85 | $26K | 30,000 |
| 2020-01-14 | HAYDEN DONALD J JR Director | Sale | −30,000 | $45.60 | $1.4M | 0 |
| 2020-01-14 | HAYDEN DONALD J JR Director | Option exercise · Stock Option (Right to Buy) | −30,000 | 159,100 | ||
| 2020-01-08 | Vasista Vittal Chief Financial Officer | Option exercise | +3,000 | $13.09 | $39K | 232,215 |
| 2020-01-08 | Vasista Vittal Chief Financial Officer | Sale | −2,400 | $41.40 | $99K | 229,815 |
| 2020-01-08 | Vasista Vittal Chief Financial Officer | Sale | −5,100 | $41.92 | $214K | 224,715 |
| 2020-01-08 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −3,000 | 29,374 | ||
| 2020-01-02 | Christmas Patrick J. SVP, General Counsel | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2020-01-02 | Simpson Curran SVP, Product Development & CTO | Grant or award · Stock Option (Right to Buy) | +46,000 | 46,000 | ||
| 2019-12-31 | Danos Olivier Chief Scientific Officer | Grant or award | +302 | $34.82 | $11K | 6,802 |
Page 25 of 25 · 494 trades